Literature DB >> 4028032

Aminoglutethimide-induced hematologic toxicity: worldwide experience.

A A Messeih, A Lipton, R J Santen, H A Harvey, A E Boucher, R Murray, J Ragaz, A U Buzdar, G A Nagel, I C Henderson.   

Abstract

Marked leukopenia and/or thrombocytopenia occurred in 12 of 1333 patients treated with aminoglutethimide (0.9% incidence). Depression of blood cell counts was evident within 7 weeks of starting treatment. No delayed toxicity was encountered. Blood cell counts recovered promptly upon cessation of aminoglutethimide in all but one patient, who died from septicemia and marrow aplasia.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4028032

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  4 in total

1.  Aminoglutethimide-induced myelosuppression.

Authors:  J T van der Heijden; T A Splinter
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

2.  Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.

Authors:  B P Haynes; M Jarman; M Dowsett; A Mehta; P E Lønning; L J Griggs; A Jones; T Powles; R Stein; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 3.  Endocrine therapy for advanced breast cancer: a review.

Authors:  H B Muss
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Neutropenia induced by aminoglutethimide in breast cancer.

Authors:  J L Steinberg; M E Trudeau
Journal:  J R Soc Med       Date:  1993-08       Impact factor: 18.000
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.